Compare LRMR & PSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LRMR | PSF |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.5M | 222.3M |
| IPO Year | 2014 | N/A |
| Metric | LRMR | PSF |
|---|---|---|
| Price | $3.03 | $18.39 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $14.40 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 71.9K |
| Earning Date | 11-24-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.69% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.92 | $17.80 |
| 52 Week High | $6.42 | $20.67 |
| Indicator | LRMR | PSF |
|---|---|---|
| Relative Strength Index (RSI) | 59.82 | 49.90 |
| Support Level | $2.89 | $17.81 |
| Resistance Level | $4.19 | $19.58 |
| Average True Range (ATR) | 0.25 | 0.38 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 95.93 | 44.75 |
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.